Monitoring Health Through Novel Technologies: Where Are We with Point-of-Care Diagnostics?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Paradigm Shift in Health Monitoring
  • Pursuit of Personalized Medicine
  • Solid Groundwork in Multiplexing Technology
• Driving Innovation for Bedside Use
• Therapeutic Areas for POC Testing
  • Cardiovascular Disease
  • Coagulation Diagnostics
  • Infl uenza Screening
  • MRSA Infections
  • Blood-Glucose Screening
• Key Movers and Shakers
• Advancing the POC Testing Market
• Main Challenges
  • Physician-Patient Pathway
  • Regulatory Maze
  • Payer Infl uence
• Outlook

Tables

• 1. Select Commercially Available Point-of-Care Tests for Cardiovascular Disease
• 2. Genetic Warfarin Sensitivity Tests
• 3. Dealmaking in the Point-of-Care Diagnostics Field, 2006-June 2009
• 4. Select Companies Marketing or Developing Pharmacogenetic Screening Tests

Figures

• 1. Market Segmentation of Point-of-Care Diagnostics
• 2. Top Ten Drugs in Personalized Medicine, 2005-2008
• 3. Ability of the Pharmacogenetic and Clinical Algorithms to Correctly Identify Patients Requiring Warfarin
• 4. Attainment and Remaining Opportunity in MRSA Infections